Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Withdrawn 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 9NIH 3INDUSTRY 2

Study Type

Observational 3Interventional 3

Sponsor

Cancer Type

Thoracic 1Head & Neck 1

Conditions

Breast Neoplasms 411Lymphoma 304Carcinoma, Non-Small-Cell Lung 262Melanoma 255Precursor Cell Lymphoblastic Leukemia-Lymphoma 251Prostatic Neoplasms 246Leukemia, Lymphocytic, Chronic, B-Cell 242Leukemia, Myeloid, Acute 222Lung Neoplasms 215Neoplasms 209Colonic Neoplasms 209Lymphoma, Non-Hodgkin 207Lymphoma, Large B-Cell, Diffuse 204Leukemia 200Multiple Myeloma 197Lymphoma, Follicular 197Colorectal Neoplasms 190Rectal Neoplasms 188Ovarian Neoplasms 184Burkitt Lymphoma 179Brain Neoplasms 171Neoplasm Metastasis 166Lymphoma, Mantle-Cell 163Carcinoma, Renal Cell 163Glioblastoma 161Sarcoma 156Pancreatic Neoplasms 147Lymphoma, B-Cell, Marginal Zone 143Unspecified Adult Solid Tumor, Protocol Specific 138Gliosarcoma 133

Interventions

pegvisomant 1alovudine 1Metformin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NIH × Interventional × Hyperplasia × Clear all
NCT02581137 2026-04-13

Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion

National Cancer Institute (NCI)

Phase 2 Active not recruiting
26 enrolled 10 charts
Head & Neck

Erythroplasia, Hyperplasia, Leukoplakia, Oral, Mouth Neoplasms

NCT01610544 2018-07-05

18F FLT Imaging Studies of Treatment Response for Lung Cancer and Thymoma

National Institutes of Health Clinical Center (CC)

Phase 2 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung, Hyperplasia, Thymoma, Thymus Neoplasms

NCT00017927 2008-03-04

A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright Syndrome

National Institutes of Health Clinical Center (CC)

Phase 3 Completed
10 enrolled

Acromegaly, Adenoma, Fibrous Dysplasia, Polyostotic, Hyperplasia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡